Is Inspire Medical Systems (INSP) Expensive As Inspire V Becomes The Main Growth Story?
Inspire Medical Systems (INSP) is in the middle of a major product transition, shifting focus to its Inspire V system. This transition is supported by expanding clinical evidence and a push to improve patient access and education.
Investors have seen mixed momentum in Inspire Medical Systems this year, with the share price climbing 50.5% over the past 90 days and 12.67% over 30 days, yet still down 25.43% on a year to date share price return and recording a 65.66% decline in the 3 year total shareholder return. This contrast suggests that recent enthusiasm around the Inspire V transition and reimbursement tailwinds is set against a longer period of weaker overall investor outcomes.
Scan beyond Inspire Medical Systems and size up other potential movers in sleep and medical technology by browsing our hand picked 38 healthcare AI stocks today.
The recent rebound in Inspire Medical Systems could be read as confidence in the Inspire V rollout and reimbursement story, or as sentiment snapping back after a harsh reset. The valuation now has to pick a side.
Most Popular Narrative: 14% Overvalued
The most followed valuation view for Inspire Medical Systems pegs fair value at $60.40, which sits below the last close at $68.81 and frames the recent rally as stretching the implied upside.
The analysts have a consensus price target of $60.4 for Inspire Medical Systems based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $85.0, and the most bearish reporting a price target of just $40.0.
See why 9 investors see Inspire Medical Systems as 14% overvalued.
Result: Fair Value of $60.40 (OVERVALUED)
Still, the Inspire Medical Systems story can be knocked off course if coding and reimbursement remain messy or if reliance on Inspire V leads to further rollout setbacks.
Find out about the key risks to this Inspire Medical Systems narrative.
Another View: Multiples Point To A Different Story For Inspire Medical Systems
The first narrative has Inspire Medical Systems looking 14% overvalued on a fair value of $60.40 versus a $68.81 share price. Yet the current P/E of 14.7x sits well below peers at 28.2x and an estimated fair ratio of 20.3x, which implies the market could move closer to that higher multiple over time. That gap frames less of a clean overpricing call and more of a debate about whether earnings risk or opportunity is being misread.
For a closer look at what the numbers imply for valuation risk and upside, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Conflicted by the mix of concern and optimism around Inspire Medical Systems? Act while the story is still forming and weigh both sides by reviewing the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Inspire Medical Systems?
Do not stop with Inspire Medical Systems when the wider market still offers pockets of value, quality and income that could better match your goals.
- Target undervalued strength by scanning companies that combine quality fundamentals with appealing pricing through our 30 high quality undervalued stocks.
- Lock in potential resilience by reviewing a list of solid balance sheet and fundamentals (24 results) that can better withstand shocks and funding pressure.
- Spot tomorrow's stories early by tracking 16 high quality undiscovered gems before attention and liquidity push them onto every watchlist.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com